<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
	<Article>
		<Journal>
			<PublisherName>Colegio Argentino de Cardioangiólogos Intervencionistas</PublisherName>
			<JournalTitle>Revista Argentina de Cardioangiología intervencionista</JournalTitle>
			<PISSN>2250-7531</PISSN>
			<EISSN>2313-9307</EISSN>
			<Volume>4</Volume>
			<Issue>02</Issue>
			<PubDate PubStatus="epublish">
				<Year>2013</Year>
				<Month>3-</Month>
				<Day>20</Day>
			</PubDate>
		</Journal>

<ArticleTitle>Percutaneous pulmonary valve implantation </ArticleTitle>
<FirstPage>0084</FirstPage>
<LastPage>0091</LastPage>
<Language>EN</Language>
<AuthorList>

	<Author>
	<FirstName>Jacqueline</FirstName>
	<MiddleName></MiddleName>
	<LastName>Kreutzer</LastName>
	<Affiliation>Associate Professor of Pediatrics, Director of Cardiac Catheterization La- boratory. Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.</Affiliation>
	<AuthorEmails>Jacqueline.kreutzer@chp.ed</AuthorEmails>
	</Author>
	
	</AuthorList>
<DOI> </DOI>
<Abstract>




Development of right ventricular outflow tract (RVOT) dysfunction due to progressive pulmonary valve stenosis and insufficiency is not uncommon after surgical repair of congenital heart disease. Since the early 90s, bare metal stenting has been considered as an approach to prolong conduit longevity. The drawback of this approach is that it only treats pulmonary stenosis leaving behind severe pulmonary valve insufficiency. Although surgical intervention in the RVOT is considered to have relatively low morbidity and mortality, it carries the inherent risks of surgery plus the known limitations in lifespan of the surgical implants such that subjects continue to require multiple open heart procedures. Percutaneous valve therapies have emerged in the last 10 years to decrease the need for open surgical procedures. As a consequence there has been a major change in the treatment of RVOT dysfunction.Author in this revision described major current transcatheter heart valves systems and also those trials involved with them: the Melody (Medtronic Inc., Minneapolis, MN) and the Edwards SAPIEN (Edwards Lifesciences, Irvine, CA). Melody valve received Humanitarian Device Exemption from the FDA in 2010 and is commercially availablein the United States. At present time percutaneous pulmonary valve implantation has been categorized as a Class II by the American Heart Association (level of evidence B).

</Abstract>
<Keywords>congenital pulmonary stenosis, pulmonary valve insufficiency, pulmonary valve replacement surgery, percutaneous pulmonary valve implantation</Keywords>
<URLs>
	<abstract>http://www.raci.com.ar/contenido/art.php?recordID=MTk2</abstract>
	<Fulltext>
		<pdf>http://recursos.meducatium.com.ar/contenido/articulos/1000840091_196/pdf/1000840091.pdf</pdf>
	</Fulltext>
</URLs>

	</Article>
</ArticleSet>